title: Acceptability and preferences for vaginal dosage forms intended for prevention of HIV or HIV and pregnancy.
abstract: This paper reviews key issues found to affect acceptability and preferences for vaginal products to prevent HIV infection or HIV and pregnancy. We focus on the interplay between the biological and physico-chemical aspects of formulation and the social and behavioral issues that may affect use. The need for an HIV prevention product that women can use is driven by women's increased biological and social vulnerability to HIV infection, and thus social and behavioral research on microbicide acceptability has been conducted alongside, as well as separate from, the earliest product development efforts. Some acceptability and preference issues are specific to a product's dosage form, use-requirements, and/or use indications, while others pertain to any vaginal product used for prevention of HIV or pregnancy. Although most of the work cited here was published since 2010, it draws on a much longer trajectory of research.
authors.affiliation: International Partnership for Microbicides, 8401 Colesville Rd., Ste 200, Silver Spring MD 20910, USA. Electronic address: cwoodsong@ipmglobal.org.
authors.forename: Cynthia
authors.initials: C
authors.lastname: Woodsong
authors.affiliation: International Partnership for Microbicides, 8401 Colesville Rd., Ste 200, Silver Spring MD 20910, USA.
authors.forename: Jonathon D S
authors.initials: JD
authors.lastname: Holt
mesh_terms: D000282:Administration, Intravaginal; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D016503:Drug Delivery Systems / Q000379:methods*; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D057240:Patient Preference; D011247:Pregnancy; D049168:Pregnancy, Unplanned; D014621:Vagina / Q000502:physiology; D066228:Vaginal Absorption; D014622:Vaginal Creams, Foams, and Jellies / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics
chemical_list: D019380:Anti-HIV Agents; D003271:Contraceptive Agents, Female; D014622:Vaginal Creams, Foams, and Jellies
keywords: HIV prevention; Microbicide acceptability; Multipurpose prevention technologies; Vaginal dosage form preferences; Vaginal microbicides